News

Regeneron Leverages Inmazeb to Combat Ebola Threats Globally

Regeneron Leverages Inmazeb to Combat Ebola Threats Globally

Regeneron Takes Action Against Ebola with Inmazeb Donation

Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) is recognized as a groundbreaking treatment approved by the U.S. Food and Drug Administration (FDA) for the Ebola infection caused by Orthoebolavirus zairense, commonly known as Zaire ebolavirus.

Currently, supply efforts are accelerating to help address the ongoing outbreak in the Democratic Republic of Congo (DRC).

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced the decision to donate up to 500 doses of Inmazeb to the World Health Organization (WHO). This donation is specifically aimed at governments in low- and lower-middle-income countries, ensuring that this crucial life-saving treatment remains accessible and free, especially where the risk of Ebola outbreaks is highest.

"Ebola poses a significant threat due to its high contagiousness and fatality rates, reaching up to 90% if left untreated," remarks Leonard S. Schleifer, M.D., Ph.D., who is the Board co-Chair, President, and Chief Executive Officer of Regeneron. He emphasizes the responsibility to alleviate barriers that could hinder patient access to this vital medicine.

Regeneron’s commitment to combating Ebola was evident during the 2018 outbreak when the company pioneered the development of Inmazeb, using their unique VelociSuite technology, which redefined the landscape of treatments available for Ebola.

Inmazeb's Role in Current Threats

In tandem with the WHO’s agreements, Regeneron is facilitating the swift delivery of Inmazeb to assist in the current outbreak in the DRC. The organization has been collaborating with various public health agencies and non-governmental organizations since 2018, providing the treatment free of charge to any nation facing an outbreak.

To date, Inmazeb has been administered to 266 patients under a compassionate use protocol, reflecting Regeneron's dedication to public health.

Understanding Inmazeb

Inmazeb is FDA-approved for treating infections caused by Orthoebolavirus zairense in both adult and pediatric populations, including newborns born to mothers who are positive for this virus. This treatment showcases Regeneron's advanced VelocImmune platform, combining three specific monoclonal antibodies to neutralize the virus effectively. By hindering the virus's ability to infect cells or rallying the immune system to target infected cells, Inmazeb stands as a significant advancement in antiviral treatment.

Clinical Success and Emerging Guidelines

The efficacy and safety of Inmazeb were notably validated through the PALM Trial, which included 681 participants during the 2018 DRC outbreak. This trial garnered attention upon its early discontinuation after establishing Inmazeb's clear superiority in reducing mortality compared to other treatments.

Since its FDA approval in 2020, Inmazeb has been highly regarded, culminating in the WHO’s inclusion of the treatment as a recommended option in 2022. Remarkably, this treatment was then added to the WHO Essential Medicines List in 2023, marking it as the inaugural Ebola treatment to achieve this status of prequalification for quality and safety.

Regeneron's Commitment to Public Health

With existing stockpiles for Inmazeb not only in the U.S. but also in various low- and middle-income nations, Regeneron's global outreach reflects their commitment to making life-saving medicines available. They have also collaborated with various governments to establish these essential stockpiles, promoting better health outcomes worldwide.

Contacting Regeneron

Media Relations
Alexandra Bowie
Phone: +1 (914) 847-3407
Email: Alexandra.Bowie@regeneron.com

Investor Relations
Mark Hudson
Phone: +1 (914) 847-3482
Email: mark.hudson@regeneron.com

Frequently Asked Questions

What is Inmazeb?

Inmazeb is an FDA-approved treatment specifically designed for infections caused by the Zaire ebolavirus, focusing on both adults and children.

How can Regeneron’s donation help countries?

The donation of Inmazeb enables vulnerable populations in low-income countries to access this treatment free of charge during Ebola outbreaks.

What are Monoclonal Antibodies?

Monoclonal antibodies are lab-made molecules engineered to serve as substitute antibodies that can restore or enhance the immune system's attack on viruses like Ebola.

Why is access to Inmazeb crucial?

Access to Inmazeb is critical as it can significantly enhance survival rates for Ebola-infected individuals, particularly in regions frequently affected by the virus.

How does Regeneron ensure distribution of Inmazeb?

Regeneron collaborates with global health organizations and governments to establish efficient supply chains and stockpiles to facilitate quick distribution during outbreaks.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 33

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 221

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Salvation Army’s Angel Tree: 2026 Holiday Cheer Drive

Updated Category News Views 100

Kickstarting Holiday Generosity: The Angel Tree Program Man, there's something heartwarming about a Christmas that shines bright for everyone. The Salvation Army's Angel Tree program is back for another season, rolling up with a mission to spark joy across the country. For over 45 years now, this initiative's been the answer to many Christmas wish lists, especially for...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 137

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 78

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 207

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 135

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Ontario Airport Braces for Holiday Travel Surge

Updated Category News Views 92

Gearing Up for a Thanksgiving Travel Boom Think Thanksgiving brings only turkey to the table? Down in Ontario, California, it's all about jet fuel and passenger counts. The Ontario International Airport (ONT) is where the skies are buzzing, forecasting over 227,000 passengers trying to soak up the holiday vibes by air. Compare that to the numbers when the local folks...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 90

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading

Top 5 Most Recently Viewed Articles

Air Products Secures $140 Million in NASA Liquid Hydrogen Contracts

Updated Category News Views 85

Air Products Receives Significant NASA Contracts Air Products, a leading supplier in the industrial gases market, recently announced an impressive contract award from NASA valued at over $140 million. This contract aims at supplying liquid hydrogen for various NASA facilities, most notably the renowned Kennedy Space Center and other significant sites where vital space...

Continue Reading
Navigating Market Realities: A Look Ahead for Investors

Updated Category News Views 158

The Uncomfortable Truth About Market Valuations Many investors may feel uneasy hearing this, but it’s essential to face the real data regarding market potential. After analyzing the last 40 years of market information from various developed economies, including movements in China, the reality might deter those banking on robust returns in the forthcoming decade. There's...

Continue Reading
Sodexo Unveils Its Universal Registration Document for 2025

Updated Category News Views 367

Introduction to Sodexo's Fiscal 2025 Document Sodexo has made significant strides in enhancing transparency and providing essential information through its recently filed Fiscal 2025 Universal Registration Document (URD). This document, which is now accessible to investors and stakeholders, showcases the company's ongoing commitment to accountability and sustainability....

Continue Reading
Paratus Energy's Q4 2025 Results: Key Indicators to Analyze

Updated Category News Views 197

Paratus Energy Services Ltd. (PLSV) is about to drop its unaudited interim Q4 2025 financial results on February 27, 2026. But here’s the kicker—traders are left with scant intel leading into this call, and that can rattle markets. First off, let’s talk about the earnings whispers. The usual playbook includes scouring through EPS projections and revenue figures, but...

Continue Reading
Keefe Adjusts Rating for Bank of N.T. Butterfield Amid Challenges

Updated Category News Views 72

Keefe Downgrades the Bank of N.T. Butterfield Stock Rating Recently, Keefe, Bruyette & Woods revised its recommendation for Bank of N.T. Butterfield (NYSE: NTB) stock, shifting the rating from Outperform to Market Perform. The price target has also been adjusted from $44 to $41. This reflects the bank's forecast of significant net interest income (NII) challenges...

Continue Reading